Page last updated: 2024-12-07
1,4-3,6-dianhydromannitol
Description
1,4:3,6-dianhydromannitol (DAM) is a cyclic ether derived from the sugar mannitol. It's a white, crystalline solid that's soluble in water and organic solvents.
Here's why DAM is important in research:
**1. Applications in Polymer Science:**
* **Crosslinking Agent:** DAM is used as a crosslinking agent for polymers, particularly for creating thermoset resins. It forms strong bonds between polymer chains, enhancing the material's strength, stiffness, and thermal stability. This is particularly useful in the development of high-performance plastics and resins used in various industries.
**2. Biomedical Applications:**
* **Drug Delivery:** DAM can be modified to create drug delivery systems. Its structure allows it to be conjugated with various drugs, leading to targeted drug delivery and controlled release. This is particularly important in areas like cancer therapy and gene delivery.
**3. Material Science:**
* **Nanomaterials:** DAM has been investigated for its role in the synthesis of nanomaterials. It can act as a template or building block for the fabrication of nanostructured materials with unique properties. This area has potential in electronics, catalysis, and energy storage.
**4. Analytical Chemistry:**
* **Chiral Analysis:** DAM derivatives can be used as chiral selectors in chromatography. This helps in separating and analyzing enantiomers, which are mirror-image molecules with different biological activities.
**5. Other Applications:**
* **Antiviral Agent:** Research suggests that DAM might have antiviral activity against certain viruses.
* **Antibacterial Agent:** Some studies indicate potential antibacterial properties of DAM, although further research is needed.
**Overall, DAM's unique chemical structure and properties make it a valuable molecule in various research fields. Its applications continue to be explored, with promising potential for advancements in materials science, drug delivery, and other areas.**
1,4-3,6-dianhydromannitol: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
PubMed CID | 99937 |
SCHEMBL ID | 244589 |
MeSH ID | M0487169 |
Synonyms (35)
Synonym |
AKOS009031419 |
einecs 248-906-7 |
mannitol, 1,4:3,6-dianhydro- |
nsc270938 |
nsc-270938 |
d-mannitol,4:3,6-dianhydro- |
OPREA1_439690 |
nsc-231906 |
nsc231906 |
2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3,6-diol |
A834663 |
einecs 211-374-1 |
nsc 270938 |
1,4-3,6-dianhydromannitol |
28218-68-0 |
FT-0606757 |
FT-0627423 |
SCHEMBL244589 |
hexahydro-furo[3,2-b]furan-3,6-diol |
hexahydrofuro[3,2-b]furan-3,6-diol |
SY003633 |
28948-16-5 |
d-sorbitol, 1,4:3,6-dianhydro |
CS-0077330 |
d-isosorbide; dianhydro-d-glucitol;dianhydrosorbitol |
BCP13451 |
CS-11040 |
SY263338 |
mfcd32202826 |
89825-36-5 |
(s)-3-ethyl-6-[(benzylamino)methyl]-1,3-oxazinan-2-one |
mannitol,1,4:3,6-dianhydro- |
EN300-20516 |
DTXSID801031676 |
d-iditol, 1,4:3,6-dianhydro- |
Research Excerpts
Dosage Studied
Excerpt | Relevance | Reference |
" NCX 667 or vehicle (30 µL) was instilled in a crossover, masked fashion and intraocular pressure (IOP) measured before dosing (baseline) and for several hours thereafter." | ( NCX 667, a Novel Nitric Oxide Donor, Lowers Intraocular Pressure in Rabbits, Dogs, and Non-Human Primates and Enhances TGFβ2-Induced Outflow in HTM/HSC Constructs. Ahmed, F; Almirante, N; Bastia, E; Bergamini, MVW; Brambilla, S; Galli, C; Impagnatiello, F; Masini, E; Navratil, T; Sgambellone, S; Toris, CB; Torrejon, KY; Unser, AM, 2021) | 0.62 |
Research
Studies (16)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 3 (18.75) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (12.50) | 29.6817 |
2010's | 7 (43.75) | 24.3611 |
2020's | 4 (25.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.91
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 11.91 (24.57) | Research Supply Index | 2.83 (2.92) | Research Growth Index | 4.74 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 16 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |